B+
Bull case
20%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
ALLO
Allogene TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A credible ALLO-329 signal and eventual confirmation that ALPHA3 MRD clearance improves event-free survival could substantially improve the platform thesis. Allogene reported $423.6 million of cash, cash equivalents and investments at June 30, 2026 and projected runway into 2029 [#SEC-8K-2026-08-12].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
ALLO-329 remains in Phase 1, with unresolved efficacy, safety and lymphodepletion questions across autoimmune indications.
Momentum
96
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.25 · Bull $2.40 · Bear $0.55Analysis 2026-10-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.75
Why
Momentum96 · Δ7d -
Value41 · Δ7d -0.1
Sentiment54 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • ALLO-329 remains in Phase 1, with unresolved efficacy, safety and lymphodepletion questions across autoimmune indications.
- • Early ALPHA3 MRD clearance may not translate into durable event-free-survival benefit; interim data may not predict final results.
- • The ALPHA3 MRD comparison is based on only 24 patients and is not an event-free-survival result.
Catalyst clock
2026-12-31
ALPHA3 site activation and enrollment execution
Lead driver: Sentiment · See AI snapshot
Momentum
96
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
54
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 96.4 / Value 40.7 / Sentiment 54.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
B
Base case
35%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-30
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$407.68M
Beta
0.60
Shares Out
345.49M
P/E (TTM) · Derived
-1.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.89
Rev YoY
-100.0%
EPS YoY
-44.3%
Gross Margin
-151.5%
Op Margin
-1241814.0%
Net Debt
-$166.96M
Current Ratio
10.72
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data